Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class i restricted CD8 T cell responses

International Journal of Cancer

Volumn 128, Issue 6, 2011, Pages 1371-1383

  Singh, Satwinder Kaur ^a   Streng Ouwehand, Ingeborg ^a   Litjens, Manja ^a   Kalay, Hakan ^a   Saeland, Eirikur ^a   Van Kooyk, Yvette ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antigen presentation; glycans; MGL2

Indexed keywords

GAMMA INTERFERON; GLYCAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYELOID DIFFERENTIATION FACTOR 88; N ACETYLGALACTOSAMINE; ONCOPROTEIN; PROTEIN MGL2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DNA SYNTHESIS; GLYCOSYLATION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ACETYLGALACTOSAMINE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BLOTTING, WESTERN; BONE MARROW CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; CROSS-PRIMING; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLYCOSYLATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID DIFFERENTIATION FACTOR 88; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPLEEN;

EID: 79551477301     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25458     Document Type: Article

References (52)

1. Underhill DM,. Toll-like receptors and microbes take aim at each other. Curr Opin Immunol 2004; 16: 483-7.
2. Engering AJ, Cella M, Fluitsma DM, Hoefsmit EC, Lanzavecchia A, Pieters J,. Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv Exp Med Biol 1997; 417: 183-7.
3. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, Nussenzweig MC,. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375: 151-5.
4. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis e Sousa,. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008; 118: 2098-110.
5. Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin TJ, Lo JC, Rizzitelli A, Wu L, Vremec D, van Dommelen SL, Campbell IK, Maraskovsky E, et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 2008; 112: 3264-73.
6. Burgdorf S, Lukacs-Kornek V, Kurts C,. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 2006; 176: 6770-6.
7. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM,. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196: 1627-38.
8. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF,. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol 2000; 30: 1714-23.
9. Bevan MJ,. Cross-priming. Nat Immunol 2006; 7: 363-5.
10. den Haan JM, Bevan MJ,. Antigen presentation to CD8+ T cells: cross-priming in infectious diseases. Curr Opin Immunol 2001; 13: 437-41.
11. Ackerman AL, Kyritsis C, Tampe R, Cresswell P,. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci USA 2003; 100: 12889-94.
12. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van EP, Amigorena S,. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003; 425: 397-402.
13. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, Thibault P, Sacks D, Desjardins M,. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003; 425: 402-6.
14. Shen L, Sigal LJ, Boes M, Rock KL,. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 2004; 21: 155-65.
15. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC,. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-79.
16. Carter RW, Thompson C, Reid DM, Wong SY, Tough DF,. Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol 2006; 177: 2276-84.
17. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, Steinman RM, Nussenzweig MC,. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315: 107-11.
18. Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, Munster D, MacDonald KP, Hart DN,. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol 2006; 18: 857-69.
19. Suzuki N, Yamamoto K, Toyoshima S, Osawa T, Irimura T,. Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen. J Immunol 1996; 156: 128-35.
20. Sato M, Kawakami K, Osawa T, Toyoshima S,. Molecular cloning and expression of cDNA encoding a galactose/N-acetylgalactosamine-specific lectin on mouse tumoricidal macrophages. J Biochem 1992; 111: 331-6.
21. Higashi N, Fujioka K, da-Nagai K, Hashimoto S, Nagai S, Sato T, Fujita Y, Morikawa A, Tsuiji M, Miyata-Takeuchi M, Sano Y, Suzuki N, et al. The macrophage C-type lectin specific for galactose/N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells. J Biol Chem 2002; 277: 20686-93.
22. Tsuiji M, Fujimori M, Ohashi Y, Higashi N, Onami TM, Hedrick SM, Irimura T,. Molecular cloning and characterization of a novel mouse macrophage C-type lectin, mMGL2, which has a distinct carbohydrate specificity from mMGL1. J Biol Chem 2002; 277: 28892-901.
23. Singh SK, Streng-Ouwehand I, Litjens M, Weelij DR, Garcia-Vallejo JJ, van Vliet SJ, Saeland E, van Kooyk Y,. Characterization of murine MGL1 and MGL2 C-type lectins: distinct glycan specificities and tumor binding properties. Mol Immunol 2009; 46 (6): 1240-9.
24. van Vliet SJ, van Liempt E, Saeland E, Aarnoudse CA, Appelmelk B, Irimura T, Geijtenbeek TB, Blixt O, Alvarez R, van Die I, van Kooyk Y,. Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. Int Immunol 2005; 17: 661-9.
25. Oo-Puthinan S, Maenuma K, Sakakura M, denda-Nagai K, Tsuiji M, Shimada I, Nakamura-Tsuruta S, Hirabayashi J, Bovin NV, Irimura T,. The amino acids involved in the distinct carbohydrate specificities between macrophage galactose-type C-type lectins 1 and 2 (CD301a and b) of mice. Biochim Biophys Acta 2008; 1780: 89-100.
26. denda-Nagai K, Kubota N, Tsuiji M, Kamata M, Irimura T,. Macrophage C-type lectin on bone marrow-derived immature dendritic cells is involved in the internalization of glycosylated antigens. Glycobiology 2002; 12 (7): 443-50.
27. Onami TM, Lin MY, Page DM, Reynolds SA, Katayama CD, Marth JD, Irimura T, Varki A, Varki N, Hedrick SM,. Generation of mice deficient for macrophage galactose- and N-acetylgalactosamine-specific lectin: limited role in lymphoid and erythroid homeostasis and evidence for multiple lectins. Mol Cell Biol 2002; 22 (14): 5173-81.
28. Dupasquier M, Stoitzner P, Wan H, Cerqueira D, van OA, Voerman JS, denda-Nagai K, Irimura T, Raes G, Romani N, Leenen PJ,. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. J Leukoc Biol 2006; 80: 838-49.
29. Iida S, Yamamoto K, Irimura T,. Interaction of human macrophage C-type lectin with O-linked N-acetylgalactosamine residues on mucin glycopeptides. J Biol Chem 1999; 274: 10697-705.
30. Saeland E, van Vliet SJ, Backstrom M, van den Berg V, Geijtenbeek TB, Meijer GA, van Kooyk Y,. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother 2007; 56: 1225-36.
31. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H,. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010; 70: 1306-13.
32. Napoletano C, Rughetti A, gervig Tarp MP, Coleman J, Bennett EP, Picco G, Sale P, denda-Nagai K, Irimura T, Mandel U, Clausen H, Frati L, et al. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res 2007; 67: 8358-67.
33. Piller V, Piller F, Cartron JP,. Comparison of the carbohydrate-binding specificities of seven N-acetyl-D-galactosamine-recognizing lectins. Eur J Biochem 1990; 191: 461-6.
34. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C,. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 2008; 9: 558-66.
35. Backer R, van LF, Kraal G, den Haan JM,. CD8- dendritic cells preferentially cross-present Saccharomyces cerevisiae antigens. Eur J Immunol 2008; 38: 370-80.
36. van Vliet SJ, Aarnoudse CA, Broks-van den Berg VC, Boks M, Geijtenbeek TB, van Kooyk Y,. MGL-mediated internalization and antigen presentation by dendritic cells: a role for tyrosine-5. Eur J Immunol 2007; 37: 2075-81.
37. Kumamoto Y, denda-Nagai K, Aida S, Higashi N, Irimura T,. MGL2 Dermal dendritic cells are sufficient to initiate contact hypersensitivity in vivo. PLoS One 2009; 4: e5619.
38. Altin JG, Parish CR,. Liposomal vaccines-targeting the delivery of antigen. Methods 2006; 40: 39-52.
39. Reddy ST, Swartz MA, Hubbell JA,. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006; 27 (12): 573-9.
40. Breckpot K, Aerts JL, Thielemans K,. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007; 14 (11): 847-62.
41. Tacken PJ, de Vries I, Torensma R, Figdor CG,. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7: 790-802.
42. Lam JS, Mansour MK, Specht CA, Levitz SM,. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 2005; 175: 7496-503.
43. Hiltbold EM, Ciborowski P, Finn OJ,. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res 1998; 58: 5066-70.
44. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ,. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000; 165: 3730-41.
45. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L, Jr. , Hanisch FG, Finn OJ,. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002; 196: 1435-46.
46. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, Schultze JL, Finn O,. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 2003; 33: 3242-54.
47. Tatsumi E, Takahashi N, Hirose M,. Denatured state of ovalbumin in high concentrations of urea as evaluated by disulfide rearrangement analysis. J Biol Chem 1994; 269: 28062-7.
48. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M,. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002; 7: 209-21.
49. Hiltbold EM, Alter MD, Ciborowski P, Finn OJ,. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cell Immunol 1999; 194: 143-9.
50. Stepensky D, Tzehoval E, Vadai E, Eisenbach L,. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006; 143: 139-49.
51. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van UK, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J,. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000; 86: 702-12.
52. Leibundgut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis e Sousa,. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8: 630-8.